



## REPURCHASED SHARES IN KARO PHARMA DURING WEEK 26 2018

STOCKHOLM 2 July 2018

During the period 25 June 2018 to 29 June 2018, Karo Pharma AB (publ) (LEI code 213800G54Z51LOPGTA79) has repurchased in total 460,816 own shares (ISIN: SE00007464888). The repurchases form part of the SEK 86.3 million share repurchase programme that Karo Pharma announced on 18 June 2018. The share repurchase programme, which runs between 18 June 2018 and 31 August 2018, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052.

During the period 25 June 2018 – 29 June 2018, shares in Karo Pharma have been repurchased as follows.

Date	Aggregated daily volume (number of shares)	Weighted average share price per day (SEK)	Total daily transaction value (SEK)
25 June 2018	104 906	29.278900	3 125 045
26 June 2018	100 000	29.206900	2 920 690
27 June 2018	78 000	29.595300	2 308 433
28 June 2018	98 332	29.657800	2 916 311
29 June 2018	79 578	28.621200	2 357 196

All acquisitions have been carried out on Nasdaq Stockholm by Swedbank in cooperation with Kepler Cheuvreux SA on behalf of Karo Pharma. Following the above acquisitions, Karo Pharma's holding of own shares amounts to 844,105 shares as of 29 June 2018. The total number of shares in Karo Pharma is 164,332,782.

A full breakdown of the transactions pursuant to article 5.3 of MAR and article 2.3 of the Safe Harbour Regulation is available at [www.karopharma.com](http://www.karopharma.com). The total volume of Karo Pharma's shares which have been bought back within the repurchase programme from 18 June 2018 until and including 29 June 2018 amounts to 844,105 shares. In total a maximum of 2 464 990 shares may be repurchased. For information about all transactions in the buy-back programme see the following link to Nasdaq Stockholm's website:

<http://www.nasdaqomx.com/transactions/markets/nordic/corporate-actions/stockholm/repurchases-of-own-shares>.

**FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

Peter Blom, CEO, +46 (0) 70-655 56 98 or [peter.blom@karopharma.se](mailto:peter.blom@karopharma.se)

**ABOUT KARO PHARMA**

Karo Pharma is a Specialty Pharma company, which develops and markets products for pharmacies as well as directly to the healthcare sector. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.

*The information was submitted for publication, through the above contact person's agency, at 08.00 CEST on 2 July 2018. This press release is also available at [www.karopharma.se](http://www.karopharma.se) and [www.newsroom.cision.com](http://www.newsroom.cision.com).*